Home Healthcare: Air Liquide Strengthens Its Presence in Europe with Two Acquisitions in Switzerland
05 Février 2019 - 8:30AM
Business Wire
Regulatory News:
Air Liquide (Paris:AI) continues to develop its home
healthcare activity in Europe with the acquisition of Sleep &
Health SA and Megamed AG, two historic players in this sector and
based in Switzerland. Air Liquide, Europe’s leader in home
healthcare, strengthens its position in a growing market within a
mature healthcare system.
Founded in 2003, Sleep & Health SA is a nationwide
player that offers home healthcare services for patients who suffer
from sleep apnea. As for Megamed AG, the company has been
present in the Swiss market for nearly 50 years, specializing in
ventilation and support for patients who suffer from respiratory
failure. Air Liquide will build on the quality of existing
teams to pursue the development of these business activities.
Present in Switzerland for many years via its subsidiary
Carbagas, Air Liquide supplies the medical gas needs of both
hospitals and patients at home. These two acquisitions thus
reinforce and diversify its home healthcare offering and enable Air
Liquide to directly serve more than 3,000 new patients. In
addition, Air Liquide will benefit from the complementarity of
Sleep & Health SA’s presence in French-speaking Switzerland and
in German-speaking Switzerland for Megamed AG, as well as from the
well-established relationships these companies have with
physicians, hospitals, and private insurers.
Thus Air Liquide continues its dynamic expansion of the home
healthcare business across Europe by strengthening its positions or
entering new markets and developing support for new diseases.
François Jackow, member of the Air Liquide Group’s
Executive Committee, supervising Healthcare activities, stated:
“We are happy to welcome the teams from Sleep & Health SA
and from Megamed AG to the Air Liquide Group. Their expertise
and their knowledge of the Swiss market, combined with the
expertise of Air Liquide, will allow us to better address the
needs of patients and healthcare professionals alike. With these
acquisitions, Air Liquide is pursuing the development of its home
healthcare business in the Swiss market, which shows high
potential. These acquisitions, which strengthen our positioning in
a growing European market, are consistent with our development
strategy in the Health activity.”
Air Liquide
HealthcareSupplies medical gases, home healthcare
services, hygiene products, medical equipment and specialty
ingredients.In 2017, it served over 15,000 hospitals and
clinics and more than 1.5 million patients at home
throughout the world. The Group’s Healthcare business reached
€3,401 million in revenues in 2017, with the support of its
16,500 employees.
The Home Healthcare
BusinessAir Liquide, European leader in home
healthcare, provides home healthcare services in compliance
with medical prescription for patients suffering from chronic
diseases such as COPD (Chronic Obstructive Pulmonary Disease),
sleep apnea and diabetes. These home healthcare services are being
developed in addition to hospital care, enabling patients to enjoy
better quality of life and local authorities to reduce costs. Home
healthcare represents 45% of Air Liquide's revenue in Healthcare
in 2017.
A world leader in gases, technologies and services for Industry
and Health, Air Liquide is present in 80 countries with
approximately 65,000 employees and serves more than 3.5 million
customers and patients. Oxygen, nitrogen and hydrogen are essential
small molecules for life, matter and energy. They embody Air
Liquide’s scientific territory and have been at the core of the
company’s activities since its creation in 1902.
Air Liquide’s ambition is to be a leader in its industry,
deliver long term performance and contribute to sustainability. The
company’s customer-centric transformation strategy aims at
profitable growth over the long term. It relies on operational
excellence, selective investments, open innovation and a network
organization implemented by the Group worldwide. Through the
commitment and inventiveness of its people, Air Liquide leverages
energy and environment transition, changes in healthcare and
digitization, and delivers greater value to all its
stakeholders.
Air Liquide’s revenue amounted to 20.3 billion euros in 2017 and
its solutions that protect life and the environment represented
more than 40% of sales. Air Liquide is listed on the Euronext Paris
stock exchange (compartment A) and belongs to the CAC 40, EURO
STOXX 50 and FTSE4Good indexes.
www.airliquide.comFollow us on Twitter
@airliquidegroup
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190204005556/en/
Corporate Communicationsmedia@airliquide.com+33 (0)1 40
62 58 49
Investor RelationsParis - France+33 (0)1 40 62 50
87Philadelphia - USA+1 610 263 8277
Air Liquide Healthcare CommunicationsCoralie Gazzeri+01
49 69 45 40
Air Liquide (EU:AI)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Air Liquide (EU:AI)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024